EYLEA® (aflibercept) 8 mg

EYLEA 114.3 mg/mL is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (nAMD) and visual impairment due to diabetic macular oedema (DMO).

STREAMLINE YOUR CLINIC WITH EYLEA 8 mg

Now with licenced treatment intervals up to 6 months*, offering flexibility and efficiency for your treatment regimen

This is based on the latest 3-year clinical trial extension data. For more information on DOSING in nAMD and DMO, please click here.

As well as giving you the chance to further streamline your clinic, EYLEA 8 mg offers a comparable safety profile to EYLEA 2 mg.

*For patients who are initiating EYLEA treatment, EYLEA is administered with 1 injection per month for 3 consecutive doses. Injection intervals may then be extended up to every 4 months based on the physician’s judgement of visual and/or anatomic outcomes. Subsequently, the treatment intervals may be further extended up to 6 months, such as with a treat-and-extend dosing regimen, while maintaining stable visual and/or anatomic outcomes. Consult the SmPC for full posology.

^†Patients could receive as few as 10 injections over 3 years as per the dosing schedules in the PULSAR and PHOTON trial protocols.

^‡Stable patients switching to EYLEA 8 mg do not require loading doses and can maintain or extend previous treatment intervals after the first injection of EYLEA. For patients who have previously been treated with EYLEA 2 mg or other anti-VEGF medicinal products and are switching to EYLEA 8 mg, the treatment regimen can differ from that used for treatment-naive patients. Treatment intervals should be determined based on visual and/or anatomic outcomes: in patients with stable visual and/or anatomic outcomes, previous treatment intervals can be maintained or extended after the first injection of EYLEA 114.3 mg/mL, such as with a treat-and-extend dosing regimen; in patients with suboptimal visual and/or anatomic outcomes, treatment with EYLEA 8 mg may begin with 1 injection per month for up to 3 consecutive doses followed by adjustment of injection intervals, such as with a treat-and-extend dosing regimen. Consult the SmPC for full posology.

^§Following 3 monthly loading doses, intervals can be extended to Q16, dependent on visual and/or anatomic outcomes, and subsequently to 6 months (e.g. with a T&E regimen) if visual and/or anatomic outcomes are stable.

GAIN CONFIDENCE IN FLUID CONTROL

In the PULSAR and PHOTON trials, EYLEA® (aflibercept) 8 mg provided lasting non-inferior vision gains with fewer injections vs EYLEA 2 mg in nAMD and DMO.

For more information on DOSING in nAMD and DMO, please click here.

Now, clinical trial and real-world evidence has shown EYLEA 8 mg can provide sustained fluid resolution whilst minimising treatment burden vs EYLEA 2 mg.

In clinical trials, EYLEA 8 mg showed:

*Primary endpoint in PULSAR and PHOTON. BCVA gains from baseline with EYLEA 8 mg were non-inferior to EYLEA 2 mg at Week 48 in both trials. Vision gains were maintained through Week 96 for EYLEA 8 mg and EYLEA 2 mg in both trials.

Recent UK audit data has shown that these RCT results are now being replicated, with the drying effect of EYLEA 8 mg observed from the first injection.

Abbreviations

2Q8, 2 mg every 8 weeks. BCVA, best-corrected visual acuity. CRT, central retinal thickness. DMO, diabetic macular oedema. nAMD, neovascular age-related macular degeneration. RCT, randomised controlled trial. SmPC, Summary of Product Characteristics. VEGF, vascular endothelial growth factor.